Osmotica Pharmaceuticals PLC (OSMT)
| Market Cap | 272.25M |
| Revenue (ttm) | 203.26M |
| Net Income (ttm) | -51.36M |
| Shares Out | 62.79M |
| EPS (ttm) | -0.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $4.31 |
| Previous Close | $4.35 |
| Change ($) | -0.04 |
| Change (%) | -0.92% |
| Day's Open | 4.39 |
| Day's Range | 4.31 - 4.52 |
| Day's Volume | 297,201 |
| 52-Week Range | 2.83 - 8.77 |
While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
One of the company's pipeline candidates ran into a regulatory hurdle.
BRIDGEWATER, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”...
Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multip...
Adamas to acquire global rights to OSMOLEX ER® for $7.5 million
-- Addition of Dr. Raymond Douglas, M.D., PhD, further enhances RVL's commitment to advancing the clinical and scientific platform supporting Upneeq -- -- Addition of Dr. Raymond Douglas, M.D....
BRIDGEWATER, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today th...
Osmotica Pharmaceuticals' (OSMT) CEO Brian Markison on Q3 2020 Results - Earnings Call Transcript
Shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) rose 4.4% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 148.28% year over year ...
Third quarter 2020 total revenue of $57.2 million
BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced th...
-- Phase 3 trials showed UPNEEQ was associated with positive outcomes after instillation on days 1 and 14 and was well-tolerated, demonstrating its potential promise for the treatment of acqui...
BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today...
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q2 2020 Results - Earnings Call Transcript
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q2 2020 Results - Earnings Call Transcript
OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 0.00% and -2.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) decreased 4.46% in after-market trading after the company reported Q2 results.
Second quarter 2020 total revenue of $37.5 million
-Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO- -Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO-
OSMOTICA PHARM (OSMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OSAKA, Japan and BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd (hereinafter, Santen) and RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuti...
BRIDGEWATER, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) through its subsidiary Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a fully ...
The company announced the pricing of a public offering of common stock.
BRIDGEWATER, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today ...
BRIDGEWATER, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today ...
Osmotica Pharmaceuticals (NASDAQ: OSMT) surged Friday, ending the day up 25.3% to close at $8.77 per share.
One of the company’s promising products was approved by the FDA.
-- First and only FDA-approved pharmacologic treatment for acquired blepharoptosis -- -- Company to host Investor Call at 10:00 a.m. ET today to discuss approval, key elements of the clinical...
-- Submission based on world’s largest database of patients treated for spasticity associated with Multiple Sclerosis -- -- Demonstrated efficacy, tolerability and one-year safety results on ...
Osmotica Pharmaceuticals (OSMT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
BRIDGEWATER, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today ...
BRIDGEWATER, N.J., May 27, 2020 /PRNewswire/ -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, today announced results...
Osmotica Pharmaceuticals PLC (OSMT) CEO Brian Markison on Q1 2020 Results - Earnings Call Transcript
Osmotica Pharmaceuticals PLC (OSMT) CEO Brian Markison on Q1 2020 Results - Earnings Call Transcript
OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 58.33% and 11.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
First quarter 2020 total revenue of $48.6 million
OSMOTICA PHARM (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q4 2019 Results - Earnings Call Transcript
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q4 2019 Results - Earnings Call Transcript
OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 500.00% and 11.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the st...
Insider buying can be an encouraging signal for potential investors. Insiders at some small-cap biotechs have made notable share purchases.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...
Osmotica Pharmaceuticals is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.
Healthcare bounced back with an outperformance starting the fourth quarter.
--PDUFA date of July 16, 2020-- --PDUFA date of July 16, 2020--
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2019 Results - Earnings Call Transcript
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2019 Results - Earnings Call Transcript
BRIDGEWATER, N.J., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced...
Results from Three Pivotal Phase III Efficacy and Safety Trials (Studies RVL-1201-201, 202 and 203) to Be Presented at Multiple Global Congresses Results from Three Pivotal Phase III Efficacy ...
--RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) is a potential first-in-class pharmacologic treatment option for acquired blepharoptosis (droopy eyelid)-- --RVL-1201 (oxymet...
About OSMT
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; Con... [Read more...]
| Industry Biotechnology | |
| CEO Brian A. Markison | Employees 379 |
| Stock Exchange NASDAQ | Ticker Symbol OSMT |
Financial Performance
In 2019, OSMT's revenue was $240.03 million, a decrease of -8.98% compared to the previous year's $263.70 million. Losses were -$270.90 million, 147.0% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for OSMT stock is "Buy." The 12-month stock price forecast is 8.40, which is an increase of 94.90% from the latest price.